Accelerator Corp launches Lodo Therapeutics, which raises $17 mln
Accelerator Corp has formed Lodo Therapeutics Corp, which has secured $17 million in Series A funding. The investors included AbbVie, Alexandria Venture Investments, ARCH Venture Partners, Eli Lilly and Company, Harris & Harris Group, Inc., Innovate NY Fund, Johnson & Johnson Innovation – JJDC, Inc., The Partnership Fund for New York City and Pfizer Venture Investments. Based in New York City, Lodo Therapeutics Corp is a developer of therapeutics derived from Accelerator's metagenomics-based small molecule discovery platform.
11 January 2016•5 mins read
